BofA Securities Downgrades FibroGen (FGEN) to Underperform, 'unfavorable catalyst pathway'

August 8, 2023 6:03 AM EDT Send to a Friend
(Updated - August 8, 2023 6:22 AM EDT)

BofA Securities analyst Jason Gerberry downgraded FibroGen (NASDAQ: FGEN) from Neutral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login